Publications by authors named "Clement Charpentier"
Brain metastases from Merkel cell carcinoma: A nationwide retrospective study.
Raphaëlle Caillot
,
Astrid Blom
,
Céleste Lebbé
,
Laetitia Da Meda
,
Marie Boileau
,
Clément Charpentier
Eur J Cancer
September 2025
Background: Merkel cell carcinoma (MCC) is an aggressive skin cancer causing distant metastases in 30 % of cases but rarely involving the brain. PD-1/PD-L1 inhibitors constitute the standard treatment of advanced MCC but their impact on brain metastases is unknown.
Methods: This retrospective study included MCC patients with central nervous system (CNS) metastases from the French CARADERM registry and the Groupe de Cancérologie Cutanée network.
Article Synopsis
- The study compares the costs and overall survival (OS) of metastatic melanoma (MM) patients treated with conventional chemotherapy (2008-2012) versus new targeted therapies (2013-2017), revealing a median OS of 158 days for chemotherapy and 395 days for targeted therapies.
- The cost per patient for chemotherapy was €10,280, while targeted therapies cost significantly more at €94,676, indicating a substantial increase in healthcare expenditures with new treatments.
- Ultimately, the study concludes that while costs and life expectancy have risen, new targeted therapies are considered cost-effective, with an incremental cost-effectiveness ratio of €90,184 per life year gained.